AI In Clinical Trials Market: 25.19% CAGR Path to 2034
Ai In Clinical Trials Market by Component Type (Software and Services), by Therapeutic Area (Oncology, More), by Clinical Trial Phase (Phase I, More), by Deployment Model (Cloud, More), by End User (Pharmaceutical and Biotech Companies, More), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034
AI In Clinical Trials Market: 25.19% CAGR Path to 2034
Access in-depth insights on industries, companies, trends, and global markets. Our expertly curated reports provide the most relevant data and analysis in a condensed, easy-to-read format.
About Market Data Pulse
Market Data Pulse is a market intelligence and research platform that helps organizations interpret changing markets, identify growth opportunities, and make informed strategic decisions. We provide syndicated market research reports, customized research solutions, competitive intelligence, and data-driven advisory support for businesses operating in rapidly evolving global industries. Market Data Pulse delivers timely insights into market size, market share, demand patterns, pricing developments, technology adoption, consumer behavior, regulatory shifts, and the competitive landscape. Our research is designed to support decision-makers at every stage of planning—from market entry and product development to investment evaluation, expansion strategy, and risk assessment.
Our analysts combine structured desk research, industry databases, company disclosures, trade information, expert inputs, and qualitative and quantitative analytical methods. This multi-source approach helps us develop practical market assessments that go beyond headline statistics and explain the forces shaping an industry. Market Data Pulse serves professionals across sectors including technology, healthcare, energy, chemicals and materials, food and beverage, consumer goods, retail, manufacturing, automotive, logistics, financial services, and emerging business segments. We focus on translating complex data into clear, decision-ready intelligence that can help companies monitor market momentum and respond with confidence. Whether clients need an off-the-shelf report, a tailored market forecast, competitor benchmarking, customer analysis, or a focused opportunity assessment, Market Data Pulse aims to provide relevant insights with clarity, consistency, and commercial value.
Market at a glance
Market at a Glance
Figure
Base Year Valuation (2025)
USD 2.68 Billion
Forecast Valuation (2034)
USD 20.24 Billion
CAGR (2026–2034)
25.19%
Forecast Period
2026–2034
Largest Regional Market
North America (42.0% share)
Dominant Segment
Software and Services (~68% of revenue)
Key Insights & Executive Summary: Ai In Clinical Trials Market
The Ai In Clinical Trials Market closed 2025 at USD 2.68 Billion and is modeled to reach USD 20.24 Billion by 2034, equal to a 25.19% CAGR. Approximately USD 4.1 Billion of incremental annual revenue is added between 2028 and 2032, concentrated in protocol optimization, enrollment forecasting, and statistical monitoring.
Ai In Clinical Trials Market Market Size (In Billion)
15.0B
10.0B
5.0B
0
2.680 B
2025
3.355 B
2026
4.200 B
2027
5.258 B
2028
6.583 B
2029
8.241 B
2030
10.32 B
2031
Sponsors drive demand. Pharmaceutical and biotech companies generate an estimated 61% of platform licensing revenue; CROs embed vendor tools into fixed-fee contracts, compressing per-study unit pricing by 10–15%.
Software outruns services. Software is roughly 68% of segment value and grows faster than implementation, which is commoditized by templated computerized system validation packages.
Oncology anchors adoption at about 34% of AI-enabled trial deployments, ahead of neurology (14%) and immunology (11%).
Cloud is the default for 57% of new deployments; on-premise installations persist mainly where data-residency rules apply.
Three structural forces explain the trajectory:
Cost and cycle-time pressure. A Phase III oncology study now exceeds USD 60 Million in direct cost; AI-assisted site selection and risk-based monitoring have cut screen-failure rates and query volumes by 20–30% in published sponsor pilots.
Regulatory accommodation. FDA guidance issued between 2023 and 2025 on model credibility assessment, plus the EMA reflection paper, converted documentation from a compliance objection into a procurement checklist.
Data volume. Extracts from the Electronic Health Records Market, wearables, and remote trial devices produce unstructured streams that legacy EDC architectures handle poorly.
Adjacent spend in the broader Healthcare Artificial Intelligence Market supplies both a funding channel and a set of competing entrants, notably imaging and diagnostics vendors moving upstream into trial endpoints.
Principal risks: uneven GxP validation expectations between FDA and non-US regulators, site infrastructure gaps outside academic medical centers, and clinician skepticism toward model-derived insights.
Segment Deep-Dive: Software and Services Dominance in Ai In Clinical Trials Market
Segment Analysis Matrix
CAGR (%)
Market Share (%)
Key Demand Driver
Software and Services
26.4%
68%
Validated trial analytics, eConsent, and risk-based monitoring licenses
Cloud Deployment
28.1%
57%
Multi-site data aggregation and remote source verification
Oncology (Therapeutic Area)
27.6%
34%
Adaptive protocol design and biomarker-driven cohort selection
Ai In Clinical Trials Market Company Market Share
Loading chart...
Software and Services: Core Revenue Engine
Software licenses and SaaS subscriptions account for 68% of segment value; the remainder sits in implementation, data migration, and managed analytics.
The Clinical Trial Software Market is consolidating around platform bundles combining EDC, eCOA, and analytics, pushing single-purpose tools into niche roles.
The Clinical Trial Management System Market remains the entry point for most sponsors; AI modules attach as upgrades rather than standalone purchases, capping average selling price growth at 4–6% annually in mature accounts.
Retention is strongest where analytics sit inside existing CTMS workflows, with top-quartile vendors reporting net revenue retention above 115%.
Oncology and Adjacent Therapeutic Demand
The Oncology Clinical Trials Market generates roughly 34% of AI trial technology revenue, reflecting protocol complexity, biomarker stratification, and higher per-patient data density.
Neuroscience and rare disease programs follow at 14% and 11%, where synthetic control arms and prognostic enrichment deliver the clearest recruitment savings.
Phase I represents about 19% of deployments but grows fastest in relative terms as dose-escalation models and safety signal detection mature.
Phase III remains the largest absolute revenue pool because validation, monitoring, and statistical analysis budgets scale with enrollment.
Deployment Model and Margin Pressure
Cloud deployment reaches 57% share and grows at 28.1%, supported by multi-site data aggregation and remote source verification.
Gross margins for pure software vendors sit near 72–78%; CRO-embedded analytics run 35–45% because of labor content.
Services margins erode as sponsors demand fixed-fee, outcome-linked contracts tied to enrollment velocity and query-rate reduction.
Cloud infrastructure costs and model retraining cycles add 3–5 percentage points of annual cost inflation for vendors without proprietary data assets.
Infrastructure gaps at mid-size sites delay full cloud migration in parts of South America and South Asia.
Strategic Implication
Vendors without proprietary trial data or regulatory-grade validation documentation will be pushed into subcontractor roles by 2028.
Bundling analytics into existing CTMS and EDC contracts is the fastest route to defensible pricing and multi-year renewals.
Primary Market Drivers & Growth Restraints in Ai In Clinical Trials Market
Factor Type
Description
Impact Level
Timeline
Driver
Cross-industry partnerships among pharma, CROs, and AI vendors
High
Short term
Driver
Demand to control drug development cost and cycle time
High
Short term
Driver
Escalating EHR and wearable data volumes
High
Medium term
Driver
Regulatory acceptance of synthetic control arms
Medium
Medium term
Driver
Shift toward precision medicine and biomarker stratification
High
Long term
Restraint
Absence of harmonized AI software standardization and GxP rules
High
Long term
Restraint
Data privacy and security compliance burdens (GDPR, HIPAA)
High
Short term
Restraint
Infrastructure gaps at sites and mid-size sponsors
Medium
Medium term
Restraint
Clinician skepticism toward AI-generated insights
Medium
Short term
Drivers dominate near-term revenue, with cost control the single strongest catalyst. Sponsors facing patent cliffs on products representing more than USD 200 Billion in cumulative revenue before 2030 are reallocating development budgets toward any tool that shortens timelines.
The AI in Drug Discovery Market and trial execution tooling now share pipelines; discovery-stage models feed endpoint selection and cohort definitions, cutting the handoff lag between preclinical and Phase I design by an estimated 15–20%.
Regulatory acceptance of synthetic control arms remains the highest-leverage medium-term catalyst, with several oncology and rare disease submissions already citing external control data.
Wearable and sensor adoption lifts data volume per patient by 3–5x versus traditional site-collected endpoints, creating downstream demand for automated cleaning and anomaly detection.
Restraints are stickier than drivers. Fragmented validation requirements force vendors to maintain parallel documentation sets for FDA, EMA, and PMDA submissions, adding 8–12% to engineering overhead.
Privacy compliance is the most immediate cost: GDPR and HIPAA alignment work consumes 10–15% of product engineering budgets at several mid-size vendors.
Site-level infrastructure gaps slow the Decentralized Clinical Trials Market in rural and lower-income geographies, where connectivity and staff training remain limiting factors.
Clinician skepticism is fading but persists in safety adjudication, where sponsors still require human review of model-flagged events before reporting.
Competitive Ecosystem & Key Vendor Profiles: Ai In Clinical Trials Market
Vendor Benchmarking Matrix
Company Name
Core Strength
Target Audience
Market Position
Medidata (Dassault Systèmes)
End-to-end EDC, Rave, and unified clinical data platform
Large pharma and global CROs
Leader
IQVIA
Real-world data, site networks, and analytics at scale
Top 20 pharma, biotech
Leader
ICON plc
Full-service CRO with embedded AI monitoring
Mid and large pharma
Leader
Parexel
Regulatory-grade trial operations plus AI feasibility
Global sponsors
Challenger
Syneos Health
Integrated clinical and commercial analytics
Mid-cap biotech
Challenger
Saama Technologies
AI data pipelines and clinical analytics layer
Large pharma data teams
Challenger
Owkin
Federated learning on multi-omics and pathology
Oncology sponsors, hospitals
Challenger
ConcertAI
Oncology real-world data and trial matching
Oncology sponsors
Challenger
Unlearn.AI
Digital twin and synthetic control generation
Phase II/III sponsors
Niche
AiCure
Visual and behavioral patient monitoring
Site networks, sponsors
Niche
The Contract Research Organization Market is the primary channel through which smaller sponsors access these tools, since most biotech firms under 200 employees lack internal data engineering capacity.
Medidata (Dassault Systèmes): anchors the category through the Rave EDC install base and cross-sells analytics into existing trials, making displacement costly for sponsors already standardized on its data model.
IQVIA: combines the largest real-world data asset with a network of investigative sites, allowing feasibility and enrollment predictions grounded in observed rather than modeled performance.
ICON plc: differentiates through regulatory submission experience, packaging AI monitoring outputs into inspection-ready documentation for FDA and EMA filings.
Parexel: targets sponsors that prioritize audit readiness over raw model sophistication, emphasizing validated workflows and traceable outputs.
Syneos Health: bridges clinical and commercial data, positioning analytics around launch readiness rather than trial execution alone.
Saama Technologies: supplies the data engineering layer underneath sponsor-built platforms, competing on pipeline flexibility rather than end-user interface.
Owkin: applies federated learning across hospital consortia, avoiding direct patient data transfer and addressing European privacy constraints structurally.
ConcertAI: holds oncology-specific longitudinal data and trial matching capabilities, competing with broader platforms on therapeutic depth.
Unlearn.AI: focuses on digital twin generation for control arms, a narrow but high-value niche with direct sample-size implications.
AiCure: uses computer vision for dose verification and adherence measurement, a defensible position in decentralized trial designs.
Strategic Milestones & Recent Developments in Ai In Clinical Trials Market
Date
Company
Event Type
Impact
Q4 2023
Owkin
M&A
Added breast imaging AI to its trial-facing diagnostics stack
Q3 2023
ConcertAI
M&A
Acquired oncology real-world data assets from ASCO's CancerLinQ
Q1 2025
Tempus AI
M&A
Added germline and somatic testing depth for trial matching
Q2 2024
Medidata (Dassault Systèmes)
Launch
Unified source data review and query management in one workspace
Q2 2025
Unlearn.AI
Partnership
Expanded digital twin programs with neurology-focused sponsors
Q1 2024
Saama Technologies
Partnership
Extended AI data pipeline deployments with large pharma data teams
Q3 2023 — ConcertAI. The acquisition of CancerLinQ's data assets consolidated oncology real-world evidence under a single vendor, raising the data-access barrier for smaller analytics firms.
Q4 2023 — Owkin. Absorbing a specialist imaging AI developer extended Owkin's federated learning network from pathology into radiology, broadening endpoint coverage for oncology trials.
Q1 2024 — Saama Technologies. Multi-year pipeline deployments with large pharma data teams signaled a shift from pilot projects to production-grade infrastructure commitments.
Q1 2025 — Tempus AI. The Ambry Genetics acquisition deepened molecular data holdings, strengthening patient-matching accuracy and increasing competitive pressure on platform incumbents.
Q2 2025 — Unlearn.AI. Expanded sponsor collaborations in neurology indicate that digital twin methods are moving from methodological pilots toward protocol design inputs.
Across these moves, the pattern is consistent: buyers of clinical AI assets are paying for data access and validation documentation, not for algorithms.
Regional Market Analysis & Growth Corridors for Ai In Clinical Trials Market
Regional Growth Comparison
Region
Projected CAGR (%)
Base Year Valuation
Primary Catalyst
Regulatory Stringency
North America
23.8%
USD 1.13 Billion
FDA guidance, sponsor density, real-world data depth
High
Europe
24.5%
USD 0.64 Billion
EMA reflection paper, hospital consortium data models
High
Asia-Pacific
28.9%
USD 0.59 Billion
Trial volume growth, site digitization, cost arbitrage
Medium to High
South America
26.2%
USD 0.16 Billion
CRO outsourcing expansion, oncology site growth
Medium
Middle East & Africa
27.4%
USD 0.16 Billion
Sovereign health investment, digital health clusters
Medium
Most Mature Market
North America holds about 42% of global revenue, anchored by sponsor headquarters and roughly 60% of global trial starts.
Adoption is broadest in risk-based monitoring and site feasibility, where ROI is measurable within a single study.
Pricing pressure is highest here, since sponsors run competitive tenders across three to five vendors.
Fastest-Growing Corridor
Asia-Pacific grows at 28.9%, with China and India adding trial volume and site digitization simultaneously.
Japan and South Korea contribute high-value oncology data but move slower on regulatory acceptance of externally derived control arms.
The Decentralized Clinical Trials Market expands fastest in ASEAN and Oceania, where remote monitoring substitutes for thin site networks.
Europe and LAMEA
Europe reaches 24.5% CAGR; GDPR constrains centralization, favoring federated architectures such as those deployed by Owkin.
South America at 26.2% benefits from CRO outsourcing and rising oncology site capacity in Brazil and Argentina.
Middle East and Africa at 27.4% depends on GCC sovereign programs and Israel's digital health ecosystem for pilot volume.
Strategic Read
Sponsors should sequence deployments: North America for validation credibility, Asia-Pacific for cost and speed.
Vendors without federated data capability will struggle in Europe, where cross-border data transfer remains the binding constraint.
Investment, M&A & Funding Activity in Ai In Clinical Trials Market
Sub-Segment
Capital Attracted (2022–2025 est.)
Representative Investors
Strategic Rationale
Clinical trial analytics platforms
USD 2.1 Billion
Growth equity, strategic CROs
Recurring revenue and sponsor lock-in
Real-world oncology data
USD 1.4 Billion
Pharma strategics, PE
Data exclusivity for trial matching
Digital twin and synthetic controls
USD 480 Million
Venture capital
Sample-size reduction economics
Patient monitoring and adherence
USD 360 Million
Venture capital, device OEMs
Decentralized trial enablement
M&A is data-led. The largest deals of the past three years targeted data holders rather than model developers, reflecting that model quality is now a commodity input.
Strategic acquirers dominate. CROs and pharma companies account for roughly 55% of disclosed transaction value, using acquisitions to shorten internal build cycles.
Venture funding concentrates late. Series C and later rounds absorb the majority of capital as investors wait for regulatory validation evidence.
High-growth targets include synthetic control generation, oncology real-world evidence, and site-facing monitoring tools with measurable screen-failure reduction.
Exit paths favor acquisition over IPO; only a small number of clinical AI firms have reached public markets.
Technology Innovation & R&D Trajectory in Ai In Clinical Trials Market
Technology
Adoption Timeline
R&D Intensity
Incumbent Impact
Trial foundation models
2026–2029
Very high
Reinforces large data holders
Digital twins and synthetic controls
2025–2028
High
Pressures placebo-heavy designs
Wearable digital endpoints
2025–2030
Medium to high
Expands data volume requirements
Federated learning networks
2024–2027
Medium
Lowers data centralization moats
Digital Twins and Synthetic Control Arms
Models trained on historical control data support sample-size reductions of 20–30% in neurology and oncology Phase II programs.
Adoption depends on regulatory precedent more than technical readiness; each accepted submission increases sponsor confidence.
The Real-World Evidence Market supplies the external comparator data these models require, linking two previously separate procurement budgets.
Trial Foundation Models
Foundation models trained on multi-omics, pathology, and clinical text are replacing task-specific models for endpoint prediction and patient matching.
The marginal cost of adding a new indication falls sharply, which favors vendors with broad data rights over those with deep but narrow datasets.
Compute and curation costs remain the binding constraint, with leading sponsors allocating USD 40–80 Million annually to data infrastructure.
Federated and Decentralized Architectures
Federated learning reduces cross-border transfer risk and structurally weakens moats built on centralized warehouses.
Wearable-derived endpoints are advancing from exploratory to primary status in neurology and cardiology studies.
Incumbent platforms that fail to expose interoperable data layers risk being reduced to system-of-record roles while analytics value migrates elsewhere.
Ai In Clinical Trials Market Segmentation
1. Component Type
1.1. Software and Services
2. Therapeutic Area
2.1. Oncology
2.2. More
3. Clinical Trial Phase
3.1. Phase I
3.2. More
4. Deployment Model
4.1. Cloud
4.2. More
5. End User
5.1. Pharmaceutical and Biotech Companies
5.2. More
Ai In Clinical Trials Market Segmentation By Geography
1. North America
1.1. United States
1.2. Canada
1.3. Mexico
2. South America
2.1. Brazil
2.2. Argentina
2.3. Rest of South America
3. Europe
3.1. United Kingdom
3.2. Germany
3.3. France
3.4. Italy
3.5. Spain
3.6. Russia
3.7. Benelux
3.8. Nordics
3.9. Rest of Europe
4. Middle East & Africa
4.1. Turkey
4.2. Israel
4.3. GCC
4.4. North Africa
4.5. South Africa
4.6. Rest of Middle East & Africa
5. Asia Pacific
5.1. China
5.2. India
5.3. Japan
5.4. South Korea
5.5. ASEAN
5.6. Oceania
5.7. Rest of Asia Pacific
Ai In Clinical Trials Market Regional Market Share
Loading chart...
Ai In Clinical Trials Market Regional Market Share
Higher Coverage
Lower Coverage
No Coverage
Ai In Clinical Trials Market REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of 25.19% from 2020-2034
Segmentation
By Component Type
Software and Services
By Therapeutic Area
Oncology
More
By Clinical Trial Phase
Phase I
More
By Deployment Model
Cloud
More
By End User
Pharmaceutical and Biotech Companies
More
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
United Kingdom
Germany
France
Italy
Spain
Russia
Benelux
Nordics
Rest of Europe
Middle East & Africa
Turkey
Israel
GCC
North Africa
South Africa
Rest of Middle East & Africa
Asia Pacific
China
India
Japan
South Korea
ASEAN
Oceania
Rest of Asia Pacific
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objective
1.4. Definitions and Assumptions
2. Executive Summary
2.1. Market Snapshot
3. Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Trends
3.4. Market Opportunity
4. Market Factor Analysis
4.1. Porters Five Forces
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL analysis
4.3. BCG Analysis
4.3.1. Stars (High Growth, High Market Share)
4.3.2. Cash Cows (Low Growth, High Market Share)
4.3.3. Question Mark (High Growth, Low Market Share)
4.3.4. Dogs (Low Growth, Low Market Share)
4.4. Ansoff Matrix Analysis
4.5. Supply Chain Analysis
4.6. Regulatory Landscape
4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
4.8. MPU Analyst Note
5. Market Analysis, Insights and Forecast, 2020-2034
5.1. Market Analysis, Insights and Forecast - by Component Type
5.1.1. Software and Services
5.2. Market Analysis, Insights and Forecast - by Therapeutic Area
5.2.1. Oncology
5.2.2. More
5.3. Market Analysis, Insights and Forecast - by Clinical Trial Phase
5.3.1. Phase I
5.3.2. More
5.4. Market Analysis, Insights and Forecast - by Deployment Model
5.4.1. Cloud
5.4.2. More
5.5. Market Analysis, Insights and Forecast - by End User
5.5.1. Pharmaceutical and Biotech Companies
5.5.2. More
5.6. Market Analysis, Insights and Forecast - by Region
5.6.1. North America
5.6.2. South America
5.6.3. Europe
5.6.4. Middle East & Africa
5.6.5. Asia Pacific
6. North America Market Analysis, Insights and Forecast, 2020-2034
6.1. Market Analysis, Insights and Forecast - by Component Type
6.1.1. Software and Services
6.2. Market Analysis, Insights and Forecast - by Therapeutic Area
6.2.1. Oncology
6.2.2. More
6.3. Market Analysis, Insights and Forecast - by Clinical Trial Phase
6.3.1. Phase I
6.3.2. More
6.4. Market Analysis, Insights and Forecast - by Deployment Model
6.4.1. Cloud
6.4.2. More
6.5. Market Analysis, Insights and Forecast - by End User
6.5.1. Pharmaceutical and Biotech Companies
6.5.2. More
7. South America Market Analysis, Insights and Forecast, 2020-2034
7.1. Market Analysis, Insights and Forecast - by Component Type
7.1.1. Software and Services
7.2. Market Analysis, Insights and Forecast - by Therapeutic Area
7.2.1. Oncology
7.2.2. More
7.3. Market Analysis, Insights and Forecast - by Clinical Trial Phase
7.3.1. Phase I
7.3.2. More
7.4. Market Analysis, Insights and Forecast - by Deployment Model
7.4.1. Cloud
7.4.2. More
7.5. Market Analysis, Insights and Forecast - by End User
7.5.1. Pharmaceutical and Biotech Companies
7.5.2. More
8. Europe Market Analysis, Insights and Forecast, 2020-2034
8.1. Market Analysis, Insights and Forecast - by Component Type
8.1.1. Software and Services
8.2. Market Analysis, Insights and Forecast - by Therapeutic Area
8.2.1. Oncology
8.2.2. More
8.3. Market Analysis, Insights and Forecast - by Clinical Trial Phase
8.3.1. Phase I
8.3.2. More
8.4. Market Analysis, Insights and Forecast - by Deployment Model
8.4.1. Cloud
8.4.2. More
8.5. Market Analysis, Insights and Forecast - by End User
8.5.1. Pharmaceutical and Biotech Companies
8.5.2. More
9. Middle East & Africa Market Analysis, Insights and Forecast, 2020-2034
9.1. Market Analysis, Insights and Forecast - by Component Type
9.1.1. Software and Services
9.2. Market Analysis, Insights and Forecast - by Therapeutic Area
9.2.1. Oncology
9.2.2. More
9.3. Market Analysis, Insights and Forecast - by Clinical Trial Phase
9.3.1. Phase I
9.3.2. More
9.4. Market Analysis, Insights and Forecast - by Deployment Model
9.4.1. Cloud
9.4.2. More
9.5. Market Analysis, Insights and Forecast - by End User
9.5.1. Pharmaceutical and Biotech Companies
9.5.2. More
10. Asia Pacific Market Analysis, Insights and Forecast, 2020-2034
10.1. Market Analysis, Insights and Forecast - by Component Type
10.1.1. Software and Services
10.2. Market Analysis, Insights and Forecast - by Therapeutic Area
10.2.1. Oncology
10.2.2. More
10.3. Market Analysis, Insights and Forecast - by Clinical Trial Phase
10.3.1. Phase I
10.3.2. More
10.4. Market Analysis, Insights and Forecast - by Deployment Model
10.4.1. Cloud
10.4.2. More
10.5. Market Analysis, Insights and Forecast - by End User
10.5.1. Pharmaceutical and Biotech Companies
10.5.2. More
11. Competitive Analysis
11.1. Company Profiles
11.1.1. Medidata (Dassault Systmes)
11.1.1.1. Company Overview
11.1.1.2. Products
11.1.1.3. Company Financials
11.1.1.4. SWOT Analysis
11.1.2. IQVIA
11.1.2.1. Company Overview
11.1.2.2. Products
11.1.2.3. Company Financials
11.1.2.4. SWOT Analysis
11.1.3. Unlearn.ai
11.1.3.1. Company Overview
11.1.3.2. Products
11.1.3.3. Company Financials
11.1.3.4. SWOT Analysis
11.1.4. Owkin
11.1.4.1. Company Overview
11.1.4.2. Products
11.1.4.3. Company Financials
11.1.4.4. SWOT Analysis
11.1.5. Saama Technologies
11.1.5.1. Company Overview
11.1.5.2. Products
11.1.5.3. Company Financials
11.1.5.4. SWOT Analysis
11.1.6. AiCure
11.1.6.1. Company Overview
11.1.6.2. Products
11.1.6.3. Company Financials
11.1.6.4. SWOT Analysis
11.1.7. Deep6.ai
11.1.7.1. Company Overview
11.1.7.2. Products
11.1.7.3. Company Financials
11.1.7.4. SWOT Analysis
11.1.8. Exscientia
11.1.8.1. Company Overview
11.1.8.2. Products
11.1.8.3. Company Financials
11.1.8.4. SWOT Analysis
11.1.9. Antidote Technologies
11.1.9.1. Company Overview
11.1.9.2. Products
11.1.9.3. Company Financials
11.1.9.4. SWOT Analysis
11.1.10. BioSymetrics
11.1.10.1. Company Overview
11.1.10.2. Products
11.1.10.3. Company Financials
11.1.10.4. SWOT Analysis
11.1.11. Euretos
11.1.11.1. Company Overview
11.1.11.2. Products
11.1.11.3. Company Financials
11.1.11.4. SWOT Analysis
11.1.12. Ardigen
11.1.12.1. Company Overview
11.1.12.2. Products
11.1.12.3. Company Financials
11.1.12.4. SWOT Analysis
11.1.13. Mendel AI
11.1.13.1. Company Overview
11.1.13.2. Products
11.1.13.3. Company Financials
11.1.13.4. SWOT Analysis
11.1.14. Phesi
11.1.14.1. Company Overview
11.1.14.2. Products
11.1.14.3. Company Financials
11.1.14.4. SWOT Analysis
11.1.15. ICON plc
11.1.15.1. Company Overview
11.1.15.2. Products
11.1.15.3. Company Financials
11.1.15.4. SWOT Analysis
11.1.16. Parexel
11.1.16.1. Company Overview
11.1.16.2. Products
11.1.16.3. Company Financials
11.1.16.4. SWOT Analysis
11.1.17. Syneos Health
11.1.17.1. Company Overview
11.1.17.2. Products
11.1.17.3. Company Financials
11.1.17.4. SWOT Analysis
11.1.18. nference
11.1.18.1. Company Overview
11.1.18.2. Products
11.1.18.3. Company Financials
11.1.18.4. SWOT Analysis
11.1.19. ConcertAI
11.1.19.1. Company Overview
11.1.19.2. Products
11.1.19.3. Company Financials
11.1.19.4. SWOT Analysis
11.1.20. SAS Institute
11.1.20.1. Company Overview
11.1.20.2. Products
11.1.20.3. Company Financials
11.1.20.4. SWOT Analysis
11.2. Market Entropy
11.2.1. Company's Key Areas Served
11.2.2. Recent Developments
11.3. Company Market Share Analysis, 2026
11.3.1. Top 5 Companies Market Share Analysis
11.3.2. Top 3 Companies Market Share Analysis
11.4. List of Potential Customers
12. Research Methodology
List of Figures
Figure 1: Ai In Clinical Trials Market Revenue Breakdown (Billion, %) by Region 2026 & 2034
Figure 2: North America Ai In Clinical Trials Market Revenue (Billion), by Component Type 2026 & 2034
Figure 3: North America Ai In Clinical Trials Market Revenue Share (%), by Component Type 2026 & 2034
Figure 4: North America Ai In Clinical Trials Market Revenue (Billion), by Therapeutic Area 2026 & 2034
Figure 5: North America Ai In Clinical Trials Market Revenue Share (%), by Therapeutic Area 2026 & 2034
Figure 6: North America Ai In Clinical Trials Market Revenue (Billion), by Clinical Trial Phase 2026 & 2034
Figure 7: North America Ai In Clinical Trials Market Revenue Share (%), by Clinical Trial Phase 2026 & 2034
Figure 8: North America Ai In Clinical Trials Market Revenue (Billion), by Deployment Model 2026 & 2034
Figure 9: North America Ai In Clinical Trials Market Revenue Share (%), by Deployment Model 2026 & 2034
Figure 10: North America Ai In Clinical Trials Market Revenue (Billion), by End User 2026 & 2034
Figure 11: North America Ai In Clinical Trials Market Revenue Share (%), by End User 2026 & 2034
Figure 12: North America Ai In Clinical Trials Market Revenue (Billion), by Country 2026 & 2034
Figure 13: North America Ai In Clinical Trials Market Revenue Share (%), by Country 2026 & 2034
Figure 14: South America Ai In Clinical Trials Market Revenue (Billion), by Component Type 2026 & 2034
Figure 15: South America Ai In Clinical Trials Market Revenue Share (%), by Component Type 2026 & 2034
Figure 16: South America Ai In Clinical Trials Market Revenue (Billion), by Therapeutic Area 2026 & 2034
Figure 17: South America Ai In Clinical Trials Market Revenue Share (%), by Therapeutic Area 2026 & 2034
Figure 18: South America Ai In Clinical Trials Market Revenue (Billion), by Clinical Trial Phase 2026 & 2034
Figure 19: South America Ai In Clinical Trials Market Revenue Share (%), by Clinical Trial Phase 2026 & 2034
Figure 20: South America Ai In Clinical Trials Market Revenue (Billion), by Deployment Model 2026 & 2034
Figure 21: South America Ai In Clinical Trials Market Revenue Share (%), by Deployment Model 2026 & 2034
Figure 22: South America Ai In Clinical Trials Market Revenue (Billion), by End User 2026 & 2034
Figure 23: South America Ai In Clinical Trials Market Revenue Share (%), by End User 2026 & 2034
Figure 24: South America Ai In Clinical Trials Market Revenue (Billion), by Country 2026 & 2034
Figure 25: South America Ai In Clinical Trials Market Revenue Share (%), by Country 2026 & 2034
Figure 26: Europe Ai In Clinical Trials Market Revenue (Billion), by Component Type 2026 & 2034
Figure 27: Europe Ai In Clinical Trials Market Revenue Share (%), by Component Type 2026 & 2034
Figure 28: Europe Ai In Clinical Trials Market Revenue (Billion), by Therapeutic Area 2026 & 2034
Figure 29: Europe Ai In Clinical Trials Market Revenue Share (%), by Therapeutic Area 2026 & 2034
Figure 30: Europe Ai In Clinical Trials Market Revenue (Billion), by Clinical Trial Phase 2026 & 2034
Figure 31: Europe Ai In Clinical Trials Market Revenue Share (%), by Clinical Trial Phase 2026 & 2034
Figure 32: Europe Ai In Clinical Trials Market Revenue (Billion), by Deployment Model 2026 & 2034
Figure 33: Europe Ai In Clinical Trials Market Revenue Share (%), by Deployment Model 2026 & 2034
Figure 34: Europe Ai In Clinical Trials Market Revenue (Billion), by End User 2026 & 2034
Figure 35: Europe Ai In Clinical Trials Market Revenue Share (%), by End User 2026 & 2034
Figure 36: Europe Ai In Clinical Trials Market Revenue (Billion), by Country 2026 & 2034
Figure 37: Europe Ai In Clinical Trials Market Revenue Share (%), by Country 2026 & 2034
Figure 38: Middle East & Africa Ai In Clinical Trials Market Revenue (Billion), by Component Type 2026 & 2034
Figure 39: Middle East & Africa Ai In Clinical Trials Market Revenue Share (%), by Component Type 2026 & 2034
Figure 40: Middle East & Africa Ai In Clinical Trials Market Revenue (Billion), by Therapeutic Area 2026 & 2034
Figure 41: Middle East & Africa Ai In Clinical Trials Market Revenue Share (%), by Therapeutic Area 2026 & 2034
Figure 42: Middle East & Africa Ai In Clinical Trials Market Revenue (Billion), by Clinical Trial Phase 2026 & 2034
Figure 43: Middle East & Africa Ai In Clinical Trials Market Revenue Share (%), by Clinical Trial Phase 2026 & 2034
Figure 44: Middle East & Africa Ai In Clinical Trials Market Revenue (Billion), by Deployment Model 2026 & 2034
Figure 45: Middle East & Africa Ai In Clinical Trials Market Revenue Share (%), by Deployment Model 2026 & 2034
Figure 46: Middle East & Africa Ai In Clinical Trials Market Revenue (Billion), by End User 2026 & 2034
Figure 47: Middle East & Africa Ai In Clinical Trials Market Revenue Share (%), by End User 2026 & 2034
Figure 48: Middle East & Africa Ai In Clinical Trials Market Revenue (Billion), by Country 2026 & 2034
Figure 49: Middle East & Africa Ai In Clinical Trials Market Revenue Share (%), by Country 2026 & 2034
Figure 50: Asia Pacific Ai In Clinical Trials Market Revenue (Billion), by Component Type 2026 & 2034
Figure 51: Asia Pacific Ai In Clinical Trials Market Revenue Share (%), by Component Type 2026 & 2034
Figure 52: Asia Pacific Ai In Clinical Trials Market Revenue (Billion), by Therapeutic Area 2026 & 2034
Figure 53: Asia Pacific Ai In Clinical Trials Market Revenue Share (%), by Therapeutic Area 2026 & 2034
Figure 54: Asia Pacific Ai In Clinical Trials Market Revenue (Billion), by Clinical Trial Phase 2026 & 2034
Figure 55: Asia Pacific Ai In Clinical Trials Market Revenue Share (%), by Clinical Trial Phase 2026 & 2034
Figure 56: Asia Pacific Ai In Clinical Trials Market Revenue (Billion), by Deployment Model 2026 & 2034
Figure 57: Asia Pacific Ai In Clinical Trials Market Revenue Share (%), by Deployment Model 2026 & 2034
Figure 58: Asia Pacific Ai In Clinical Trials Market Revenue (Billion), by End User 2026 & 2034
Figure 59: Asia Pacific Ai In Clinical Trials Market Revenue Share (%), by End User 2026 & 2034
Figure 60: Asia Pacific Ai In Clinical Trials Market Revenue (Billion), by Country 2026 & 2034
Figure 61: Asia Pacific Ai In Clinical Trials Market Revenue Share (%), by Country 2026 & 2034
List of Tables
Table 1: Ai In Clinical Trials Market Revenue Billion Forecast, by Component Type 2020 & 2034
Table 2: Ai In Clinical Trials Market Revenue Billion Forecast, by Therapeutic Area 2020 & 2034
Table 3: Ai In Clinical Trials Market Revenue Billion Forecast, by Clinical Trial Phase 2020 & 2034
Table 4: Ai In Clinical Trials Market Revenue Billion Forecast, by Deployment Model 2020 & 2034
Table 5: Ai In Clinical Trials Market Revenue Billion Forecast, by End User 2020 & 2034
Table 6: Ai In Clinical Trials Market Revenue Billion Forecast, by Region 2020 & 2034
Table 7: North America Ai In Clinical Trials Market Revenue Billion Forecast, by Component Type 2020 & 2034
Table 8: North America Ai In Clinical Trials Market Revenue Billion Forecast, by Therapeutic Area 2020 & 2034
Table 9: North America Ai In Clinical Trials Market Revenue Billion Forecast, by Clinical Trial Phase 2020 & 2034
Table 10: North America Ai In Clinical Trials Market Revenue Billion Forecast, by Deployment Model 2020 & 2034
Table 11: North America Ai In Clinical Trials Market Revenue Billion Forecast, by End User 2020 & 2034
Table 12: North America Ai In Clinical Trials Market Revenue Billion Forecast, by Country 2020 & 2034
Table 13: United States Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 14: Canada Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 15: Mexico Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 16: South America Ai In Clinical Trials Market Revenue Billion Forecast, by Component Type 2020 & 2034
Table 17: South America Ai In Clinical Trials Market Revenue Billion Forecast, by Therapeutic Area 2020 & 2034
Table 18: South America Ai In Clinical Trials Market Revenue Billion Forecast, by Clinical Trial Phase 2020 & 2034
Table 19: South America Ai In Clinical Trials Market Revenue Billion Forecast, by Deployment Model 2020 & 2034
Table 20: South America Ai In Clinical Trials Market Revenue Billion Forecast, by End User 2020 & 2034
Table 21: South America Ai In Clinical Trials Market Revenue Billion Forecast, by Country 2020 & 2034
Table 22: Brazil Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 23: Argentina Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 24: Rest of South America Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 25: Europe Ai In Clinical Trials Market Revenue Billion Forecast, by Component Type 2020 & 2034
Table 26: Europe Ai In Clinical Trials Market Revenue Billion Forecast, by Therapeutic Area 2020 & 2034
Table 27: Europe Ai In Clinical Trials Market Revenue Billion Forecast, by Clinical Trial Phase 2020 & 2034
Table 28: Europe Ai In Clinical Trials Market Revenue Billion Forecast, by Deployment Model 2020 & 2034
Table 29: Europe Ai In Clinical Trials Market Revenue Billion Forecast, by End User 2020 & 2034
Table 30: Europe Ai In Clinical Trials Market Revenue Billion Forecast, by Country 2020 & 2034
Table 31: United Kingdom Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 32: Germany Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 33: France Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 34: Italy Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 35: Spain Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 36: Russia Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 37: Benelux Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 38: Nordics Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 39: Rest of Europe Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 40: Middle East & Africa Ai In Clinical Trials Market Revenue Billion Forecast, by Component Type 2020 & 2034
Table 41: Middle East & Africa Ai In Clinical Trials Market Revenue Billion Forecast, by Therapeutic Area 2020 & 2034
Table 42: Middle East & Africa Ai In Clinical Trials Market Revenue Billion Forecast, by Clinical Trial Phase 2020 & 2034
Table 43: Middle East & Africa Ai In Clinical Trials Market Revenue Billion Forecast, by Deployment Model 2020 & 2034
Table 44: Middle East & Africa Ai In Clinical Trials Market Revenue Billion Forecast, by End User 2020 & 2034
Table 45: Middle East & Africa Ai In Clinical Trials Market Revenue Billion Forecast, by Country 2020 & 2034
Table 46: Turkey Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 47: Israel Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 48: GCC Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 49: North Africa Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 50: South Africa Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 51: Rest of Middle East & Africa Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 52: Asia Pacific Ai In Clinical Trials Market Revenue Billion Forecast, by Component Type 2020 & 2034
Table 53: Asia Pacific Ai In Clinical Trials Market Revenue Billion Forecast, by Therapeutic Area 2020 & 2034
Table 54: Asia Pacific Ai In Clinical Trials Market Revenue Billion Forecast, by Clinical Trial Phase 2020 & 2034
Table 55: Asia Pacific Ai In Clinical Trials Market Revenue Billion Forecast, by Deployment Model 2020 & 2034
Table 56: Asia Pacific Ai In Clinical Trials Market Revenue Billion Forecast, by End User 2020 & 2034
Table 57: Asia Pacific Ai In Clinical Trials Market Revenue Billion Forecast, by Country 2020 & 2034
Table 58: China Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 59: India Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 60: Japan Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 61: South Korea Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 62: ASEAN Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 63: Oceania Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 64: Rest of Asia Pacific Ai In Clinical Trials Market Revenue (Billion) Forecast, by Application 2020 & 2034
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
Primary research accounts for 70–80% of total effort, with secondary research covering the remaining 20–30%.
We conduct structured interviews with AI clinical trial platform vendors, contract research organizations providing decentralized trial services, sponsor-side clinical data management teams, site management organizations and investigative site networks, and regulatory technology consultancies focused on GxP software validation.
Interview targets include Head of Clinical Data Management, Vice President of Clinical Operations, Director of Regulatory Affairs (Digital Health), and Chief Medical Officer / Medical Director at sponsor organizations.
We also engage recognized bodies including the Clinical Data Interchange Standards Consortium (CDISC), the Society for Clinical Data Management (SCDM), FDA CDER, and the European Medicines Agency (EMA) for regulatory-position validation.
Interviews are conducted quarterly, with follow-up verification calls scheduled as new guidance is published.
Key Stakeholders Interviewed
Key Stakeholders Interviewed
Stakeholder Role
Interview Share (%)
Head of Clinical Data Management
28%
Vice President of Clinical Operations
26%
Director of Regulatory Affairs (Digital Health)
24%
Chief Medical Officer / Medical Director
22%
Industry Ecosystem Breakdown
Industry Ecosystem Breakdown
Company Type
Representation (%)
AI Clinical Trial Software Vendors
32%
Contract Research Organizations (CROs)
24%
Pharmaceutical & Biotech Sponsors
22%
Investigative Site Networks & SMOs
12%
Regulatory & Data Standards Bodies
10%
Secondary Research & Industry Benchmarking
Secondary sources include peer-reviewed literature on model validation, sponsor 10-K disclosures, clinicaltrials.gov registry trends, and vendor technical documentation.
Financial and transaction databases used: Bloomberg, Factiva, Hoovers, and PitchBook.
Every report is updated to the date of purchase, with pricing, regulatory, and vendor landscape changes reflected in the delivered version.
Demand Modeling & Market Estimation
Top-down and bottom-up methodologies are applied simultaneously and reconciled through multi-level data triangulation.
The bottom-up model is built from quantitative inputs including the number of active interventional trials initiated per year by phase and therapeutic area, the average AI software spend per active trial, the share of sponsors with production-grade AI deployments, and the average annual subscription value per sponsor account.
Segment splits are cross-checked against vendor revenue disclosures, CRO segment reporting, and clinical trial volume data from registries.
Regional estimates combine trial-start volume, site digitization indices, and regulatory stringency scoring to adjust technology attach rates.
The 2026–2034 forecast applies a blended growth function that separates software subscription growth from services labor growth.
Data Accuracy & Quality Check
Every deliverable carries a guaranteed estimated data accuracy level of 85–90%.
Triangulation requires convergence across at least three independent data streams before any segment figure is finalized.
Vendor-reported figures are discounted where definitions of clinical AI revenue differ from our taxonomy, and reconciliation notes are retained in the audit file.
Regional and segment forecasts are stress-tested against low, base, and high regulatory-adoption scenarios.
Final quality review is performed by a senior analyst and a category lead before release, with open assumptions documented for client review.
Frequently Asked Questions
1. What are the barriers to entry in the Ai In Clinical Trials Market and how strong are incumbent moats?
The hardest barrier is validated software: sponsors require 21 CFR Part 11 and GxP-compliant audit trails, and building that documentation typically takes 18 to 24 months. Incumbents such as Medidata and IQVIA also hold multi-year master service agreements that bundle EDC, CTMS, and analytics, making displacement expensive. Proprietary longitudinal trial data is the second moat, since model accuracy depends on labeled endpoints that new entrants cannot license quickly.
2. Which end-user industries drive demand and how do their purchasing patterns differ?
Pharmaceutical and biotech sponsors generate about 61% of platform licensing revenue, with oncology programs alone accounting for roughly 34% of AI-enabled trial deployments. Contract research organizations buy differently, embedding vendor tools inside fixed-fee study contracts and pushing unit prices down 10 to 15%. Academic research networks and government-funded trial consortia form a smaller but technically influential third tier that validates new methods before sponsors adopt them.
3. Which region dominates the AI In Clinical Trials Market and why?
North America holds about 42% of global revenue, supported by the largest concentration of sponsor headquarters, roughly 60% of global trial starts, and an FDA framework that has issued AI-related guidance since 2023. The region also hosts the deepest pool of real-world oncology data through networks such as ConcertAI and Flatiron. High per-study technology budgets and mature site IT infrastructure reinforce the lead, though cost pressure is pushing some Phase I work offshore.
4. What disruptive technologies or substitutes could reshape trial analytics?
Foundation models trained on multi-omics and clinical text are beginning to replace task-specific models for endpoint prediction and patient matching, which lowers the marginal cost of adding new indications. Synthetic control arms offer a substitute for placebo enrollment and have gained partial regulatory acceptance in rare disease and oncology settings. Federated learning architectures reduce the need to centralize patient data, weakening the advantage of vendors whose moat rests on data warehousing rather than model quality.
5. Which region is growing fastest and where are the emerging opportunities?
Asia-Pacific is the fastest-growing region at a projected 28.9% CAGR, led by China and India, where trial volumes expanded sharply after 2020 and site digitization is still early. South Korea and ASEAN markets are attracting sponsor interest for oncology and metabolic studies with lower per-patient costs. Middle East and Africa is smaller but grows near 27.4%, driven by GCC sovereign health investments and Israel's dense digital health cluster.
6. What technological innovations and R&D trends are shaping the industry?
Digital twin models generated from historical control data, used by firms such as Unlearn.AI, are the most commercially advanced innovation and have supported Phase II and Phase III sample-size reductions of 20 to 30%. Wearable-derived digital endpoints are moving from pilot to primary endpoint status in neurology and cardiology studies, requiring new validation pathways. R&D spending by the top 20 sponsors on decentralized and AI-enabled trial infrastructure grew from roughly USD 900 Million in 2021 to an estimated USD 2.4 Billion in 2025.
